Ipca Laboratories Ltd. (IPCALAB)
Market Closed
10 Aug, 22:00
MSE XNSE Primary MSE ₹
1,686. 20
-50.65
-2.9162%
₹
- Market Cap
- P/E Ratio
8% Div Yield
20,050 Volume
- Eps
₹ 1,736.85
Previous Close Want to track IPCALAB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
IPCALAB closed today lower at ₹1,686.2, a decrease of -2.9162% from yesterday's close, completing a monthly decrease of -1.9509% or -₹33.55. Over the past 12 months, IPCALAB stock gained 18.4088%.
IPCALAB pays dividends to its shareholders, with the most recent payment made on Sep 10, 2025. The next announced payment will be in In 4 weeks on Sep 10, 2026 for a total of ₹6.
The last earnings report, released on Jun 03, 2026, missed the consensus estimates by -8.2%. On average, the company has fell short of earnings expectations by -2.7333%, based on the last three reports.
Ipca Laboratories Ltd. has completed 4 stock splits, with the recent split occurring on Jan 10, 2022.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XNSE (INR).
IPCALAB Chart
Ipca Laboratories Ltd. (IPCALAB) FAQ
What is the stock price today?
The current price is ₹1,686.20.
On which exchange is it traded?
Ipca Laboratories Ltd. is listed on MSE.
What is its stock symbol?
The ticker symbol is IPCALAB.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 8%.
What is its market cap?
As of today, no market cap data is available.
Has Ipca Laboratories Ltd. ever had a stock split?
Ipca Laboratories Ltd. had 4 splits and the recent split was on Jan 10, 2022.
Ipca Laboratories Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Pranay Premchand Godha CEO | MSE Exchange | INE571A01038 ISIN |
| India Country | 17,335 Employees | 7 Aug 2026 Last Dividend | 22 Mar 2010 Last Split | - IPO Date |
Overview
Ipca Laboratories Limited is a renowned entity in the pharmaceutical sector, dedicated to the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) catering to a diverse range of therapeutic segments across the globe. With its roots planted in Mumbai, India since its incorporation in 1949, the company has expanded its reach to various international markets including Europe, Africa, the Americas, Asia, CIS, and Australasia. Ipca Laboratories stands out in the pharmaceutical industry for its comprehensive product range that addresses a multitude of health conditions, supported by a strong commitment to quality and innovation.
Products and Services
- Active Pharmaceutical Ingredients (APIs) - Ipca Laboratories produces APIs critical for the manufacturing of medicines, focusing on therapeutic areas such as anti-hypertensive, anti-malarial, diuretic, DMARD (Disease-Modifying Anti-Rheumatic Drugs), and anthelmintic. These ingredients form the backbone of many essential medications, contributing significantly to global healthcare.
- Generic and Branded Formulations - The company's extensive portfolio includes both generic and branded formulations across various therapeutic segments. This encompasses:
- Allergy Medications
- Anti-neoplastic/Cancer Drugs
- Anti-arthritic Treatments
- Anti-epileptic Drugs
- Anti-hypertensive and Cardiology Medications
- Diabetes and Diabetology Treatments
- Dermatology and Emollients/Protectives
- Fever Management
- Gastroenterology
- Hematology
- Helminthics for Parasitic Worm Infections
- Hepatoprotectives
- Immunosuppressants
- Infectious Disease Treatments
- Malaria Medications
- Neurology and Neuropathic Pain Management
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Nutraceuticals
- Ophthalmology
- Oral Anti Diabetes Drugs
- Orthopedics
- Probiotics
- Psychiatry
- Respiratory Treatments
- Rheumatology
- Urology
Contact Information
Address: 125, Kandivli Industrial Estate
Phone: 91 22 6210 5000
Website: https://www.ipca.com
